MARKET WIRETradingView • 15h ago
Nephros, Inc. Estimates – NASDAQ:NEPHTradingView report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.
Why NEPH Stock dropped -3.06% Today — RQD Quant Desk Flash
$3.17 -3.06% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $3.15
Nephros Inc. (NEPH) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C- • HOLD / WATCH
Cap $34.5M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on NEPH Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is NEPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Nephros Inc. (NASDAQ: NEPH) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $3.17 (-3.06% 1D, market cap $34.5M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, NEPH ranks #176 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does NEPH compare to TELA and CVRX in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), NEPH carries a Roarable C- (59/100 RQD), trailing P/E of 29.8x, gross margin of 61.9%, and ROIC of 18.9%. By comparison, TELA (TELA Bio Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $36.6M) and CVRX (CVRx Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $37.6M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for NEPH?
▼
Per NEPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001196298), Nephros Inc. generated $18.8M in revenue (+32.7% YoY), $1.2M in net income, and $1.6M in free cash flow against $13.6M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (62% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $3.15 (-0.74%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 8.5% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY • 53.1% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C-
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE+0.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NEPH)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (59/100 Composite)
🔍 WHY NEPH SCORES 59/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (27% of score)
SEC XBRL FY 2025 (10-K): 8.5% FCF Margin ($1.6M FCF) & 61.9% Gross Margin
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+15/20 pts (25% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade B-$3.59-1.9% Next Q
67
Q2 (-2Q)Grade C+$3.52-0.3% Next Q
64
Q3 (-1Q)Grade C+$3.51-9.7% Next Q
62
CurrentGrade C-$3.17+0.2% Hist 90D α
59
Trajectory: B- (67) → C- (59)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the NEPH Bull Thesis Could Fail
Even with a 59/100 (C-) score, NEPH faces multiple-compression risk if 29.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 59.4% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($3.86) or 200D SMA ($3.66) invalidates the momentum regime and cuts Target Base ($3.18) toward Bear Floor ($2.48).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $NEPH• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NEPH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why NEPH Stock dropped -3.06% Today — RQD Quant Desk Flash
Nephros Inc. (NEPH) dropped -3.06% to $3.17, trading at 14% of its 52-week range ($2.66 – $6.42). Solid 62% profit margin (19% return on capital), mixed timing at 30x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 14% of its 52-week range ($2.66 – $6.42) with RSI-14 at 38 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $3.17 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C- (Hold) backed by 61.9% gross margin and $1.6M annual free cash flow.
Live NEPH Headlines & Catalysts
MARKET WIREYahoo! Finance Canada • 18h ago
Nephros, Inc. (NEPH) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 21h ago
Nephros Inc. (NEPH) Edges Lower to $3.52 as Shares Sit Midway Between Key Support and Resistance - Late Stage Breakoutshttps://www.siam.in/ report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Davion Healthcare Plc (DAVI) Stock Price, News & AnalysisStock Titan report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Nephron Pharmaceuticals’ CEO is out. Here’s past coverage of the company.Yahoo Finance report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Lou Kennedy is no longer Nephron Pharmaceuticals CEOYahoo Finance report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Nephron's Lou Kennedy out as CEO in 'leadership transition’. What we know.Yahoo Finance report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETraders Union • 1d ago
Nephros, Inc. (NEPH) Stock Price Prediction for 2026, 2030-2040Traders Union report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 4d ago
Nephros Schedules Third Quarter 2026 Financial Results Conference CallSOUTH ORANGE, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will fi
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (NEPH Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
NEPH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +3.26%🛡️ HOLDING TREND SUPPORT
2026-11-03O $3.27H $3.27L $3.17C $3.17VOL 12.4K
RES: $5.70SUP: $2.99SMA50: $3.86SMA200: $3.66
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
NEPH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
23.0%/yr Implied 5Y Growth
vs. +32.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on NEPH today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for NEPH. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NEPH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NEPH)
Health Care Rank #176 of 1016
⚔️ TELA vs NEPH Full Matrix →
1. Head-to-Head Health Care Peer Comparison (NEPH vs. TELA, CVRX, BEAT, XTNT)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Nephros Inc. (NEPH) ranks #176 by composite RQD confidence (59/100, grade C-) and #784 by equity capitalization ($34.5M). Within this direct 5-issuer industry benchmark cohort, NEPH leads on earnings valuation at 29.8x trailing P/E, while NEPH leads on capital efficiency and profitability with 18.9% ROIC and 61.9% gross margin. XTNT currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with NEPH at 59/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NEPH
ACTIVE
Nephros Inc. | C- | 59/100 | 29.8x | 61.9% | 18.9% | -3.06% | $34.5M | Benchmark Subject |
| TELA TELA Bio Inc. | D- | 35/100 | — | 67.7% | -35.0% | -11.95% | $36.6M | /tela-vs-neph → |
| CVRX CVRx Inc. | E | 31/100 | — | 85.3% | -35.0% | -1.05% | $37.6M | /cvrx-vs-neph → |
| BEAT Heartbeam Inc. | D- | 42/100 | — | — | -35.0% | +2.06% | $31.0M | /beat-vs-neph → |
| XTNT Xtant Medical Holdings Inc. | C | 65/100 | — | 62.9% | 12.8% | -3.51% | $39.3M | /xtnt-vs-neph → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001196298In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nephros Inc. (NEPH) reported GAAP revenue of $18.8M (+32.7% vs. FY2024 revenue of $14.2M , and +32.0% cumulative change since FY2023) , GAAP net income of $1.2M, operating cash flow of $1.6M, and free cash flow of $1.6M (+392.5% YoY). On the balance sheet, NEPH closed FY2025 with $13.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $18.8M | $1.2M | $1.6M | $1.6M | $13.6M | — |
| FY2024 (FY) | 2024-12-31 | $14.2M | $74.0K | -$492.0K | -$547.0K | $11.2M | — |
| FY2023 (FY) | 2023-12-31 | $14.2M | -$1.6M | $827.0K | $827.0K | — | — |
3. NEPH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs NEPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Nephros Inc. (NASDAQ: NEPH) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $3.17 (-3.06% 1D, market cap $34.5M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, NEPH ranks #176 in composite RQD confidence.
How does NEPH compare to TELA and CVRX in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), NEPH carries a Roarable C- (59/100 RQD), trailing P/E of 29.8x, gross margin of 61.9%, and ROIC of 18.9%. By comparison, TELA (TELA Bio Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $36.6M) and CVRX (CVRx Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $37.6M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for NEPH?
Per NEPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001196298), Nephros Inc. generated $18.8M in revenue (+32.7% YoY), $1.2M in net income, and $1.6M in free cash flow against $13.6M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (62% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is NEPH trading relative to its 50-day, 200-day, and 52-week technical levels?
NEPH last traded at $3.17 (-3.06% on volume of 12,421 shares), positioning the stock -17.88% below its 50-day simple moving average ($3.86) and -13.39% below its 200-day simple moving average ($3.66). Across its 52-week range of $2.66 to $6.42, NEPH sits at the 13.6% percentile with a 14-day RSI of 38.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.77 to $3.57).
NEPH Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is NEPH stock moving today?
Why NEPH Stock dropped -3.06% Today — RQD Quant Desk Flash. Solid 62% profit margin (19% return on capital), mixed timing at 30x P/E—hold if owned, no rush to chase.
ROARABLE RATING BRIEF • RQD 59/100 (C-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
NEPH — Nephros Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:48:13Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, NEPH scores 59 out of 100, equating to a C- grade and a "Roarable Hold — Cautious Neutral" verdict. The five pillars are:
- Fundamental Cash Engine: 16 / 20. Per the Roarable RQD rating, this reflects ROIC of 18.9% and an FCF yield of 4.5%. This is the strongest pillar and suggests the business currently converts capital into returns at a respectable rate relative to its market value.
- Whale 13F Flow: 3 / 20. Per the Roarable RQD rating, institutional accumulation and options positioning score very low. For a prospective investor, this implies limited evidence of large institutional conviction behind the stock.
- Insider Conviction: 15 / 20. Per the Roarable RQD rating, SEC Form 4 and Congressional PTR cluster flow scores moderately well. The pillar is supported by the rating but the underlying insider transactions are not itemized in the source data.
- Macro Regime Fit: 10 / 20. Per the Roarable RQD rating, beta of 1.0 and sector sensitivity produce a middling score, indicating the stock tracks broad market movement without a clear macro tailwind.
- Forensic Balance Sheet: 15 / 20. Per the Roarable RQD rating, Altman Z of 2.5, Piotroski F of 8/9, and Debt/Equity of 0.5 support a reasonably sound balance sheet.
Investment implications: the rating's strengths are cash generation and balance sheet quality; its weaknesses are institutional demand and macro fit. Valuation is the central tradeoff. Per the Market Data section, P/E (TTM) is 29.8 and EV/EBITDA is 26.3, which are elevated multiples for a company with a 6.1% operating margin. A prospective investor would need to weigh the 18.9% ROIC against these multiples and the thin institutional support. This is an educational summary of the rating, not personalized advice.
Snapshot
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $18.8M | $1.1M | $1.2M | N/A | $1.6M | $5.4M | N/A |
| FY 2024 | $14.2M | $0.0M | $0.1M | N/A | $-0.5M | $3.8M | N/A |
| FY 2023 | $14.2M | $-1.6M | $-1.6M | N/A | $0.8M | N/A | N/A |
Per the SEC financials, revenue rose from $14.2M in FY 2024 to $18.8M in FY 2025, and net income moved from $0.1M to $1.2M. Per the market data, operating margin is 6.1% and net margin is 6.4%, with ROIC at 18.9%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 8/9, with Debt/Equity of 0.5. Debt figures are not reported in the financials table.
Open Questions
- What is the debt balance and maturity profile, given that debt is reported as N/A across all periods?
- What drove the swing from a $1.6M operating loss in FY 2023 to $1.1M operating income in FY 2025?
- Who are the institutional and insider holders, and what is their recent transaction activity?
- Does the FY 2024 revenue figure ($14.2M) correctly match the FY 2023 figure, or does it reflect a reporting issue?
- Which company is the subject of the Nephron Pharmaceuticals CEO news, and is it related to NEPH?
NEPH Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Nephros Inc. (NEPH) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 15h ago
Nephros, Inc. Estimates – NASDAQ:NEPH TradingView report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 18h ago
Nephros, Inc. (NEPH) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 21h ago
Nephros Inc. (NEPH) Edges Lower to $3.52 as Shares Sit Midway Between Key Support and Resistance - Late Stage Breakouts https://www.siam.in/ report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Davion Healthcare Plc (DAVI) Stock Price, News & Analysis Stock Titan report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Nephron Pharmaceuticals’ CEO is out. Here’s past coverage of the company. Yahoo Finance report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Lou Kennedy is no longer Nephron Pharmaceuticals CEO Yahoo Finance report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Nephron's Lou Kennedy out as CEO in 'leadership transition’. What we know. Yahoo Finance report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Traders Union • 1d ago
Nephros, Inc. (NEPH) Stock Price Prediction for 2026, 2030-2040 Traders Union report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
NEPH Bull vs. Bear Conversation Board — What's Your Call at $3.17?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NEPH 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $3.53 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is NEPH (C- • RQD 59/100) a Buy at $3.27?
Welcome to the NEPH (Nephros Inc.) Roar Pit. Current RQD Composite is 59/100 (Roarable Hold — Cautious Neutral) in Medical/Dental Instruments. Bulls point to capital efficiency (18.9% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $2.62 (-19.9%)
Spot @ $3.27 Pump the brakes on NEPH — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on NEPH, but look at what you are paying: 29.8x trailing P/E with 61.9% gross margins. Unless Nephros Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH
🎯 Target: $4.19 (+28.1%)
Spot @ $3.27 NEPH cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on NEPH, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $3.27 (52-wk range $2.66 - $6.42), any beat on forward guidance forces shorts and underweight funds to chase.